share_log

Acrivon Therapeutics, Inc.'s Quiet Period To End on December 26th (NASDAQ:ACRV)

Acrivon Therapeutics, Inc.'s Quiet Period To End on December 26th (NASDAQ:ACRV)

阿克里馮治療, 公司. '的安靜期將於 12 月 26 日結束 (納斯達克:ACRV)
Defense World ·  2022/12/19 14:21

Acrivon Therapeutics' (NASDAQ:ACRV – Get Rating) quiet period is set to end on Monday, December 26th. Acrivon Therapeutics had issued 7,550,000 shares in its IPO on November 15th. The total size of the offering was $94,375,000 based on an initial share price of $12.50. During Acrivon Therapeutics' quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

阿裡馮治療公司(納斯達克代碼：ACRV-GET Rating)的靜默期將於12月26日(星期一)結束。Acrivon治療公司在11月15日的首次公開募股中發行了7,550,000股票。根據12.50美元的初始股價，此次發行的總規模為94,375,000美元。在阿裡馮治療公司的靜默期內，由於美國證券交易委員會的監管規定，參與首次公開募股的內部人士和承銷商被限制發佈任何研究報告或對公司的收益預期。在該公司的靜默期結束後，作為承銷商的券商可能會啟動對該公司的研究報道。

Analyst Upgrades and Downgrades

分析師升級和下調評級

Several research analysts have issued reports on the stock. Cowen assumed coverage on shares of Acrivon Therapeutics in a research report on Monday, December 12th. They issued an "outperform" rating on the stock. Piper Sandler assumed coverage on shares of Acrivon Therapeutics in a research report on Sunday, December 11th. They issued an "overweight" rating and a $25.00 price target on the stock. Cowen assumed coverage on shares of Acrivon Therapeutics in a research report on Monday, December 12th. They issued an "outperform" rating on the stock. Finally, Jefferies Financial Group assumed coverage on shares of Acrivon Therapeutics in a research report on Monday, December 12th. They issued a "buy" rating and a $17.00 price target on the stock.

幾位研究分析師已經發布了關於該股的報告。考恩在12月12日星期一的一份研究報告中對Acrivon Treeutics的股票進行了報道。他們對該股給予了“跑贏大盤”的評級。派珀·桑德勒在12月11日週日的一份研究報告中對Acrivon Treeutics的股票進行了報道。他們對該股給予了“增持”評級和25.00美元的目標價。考恩在12月12日星期一的一份研究報告中對Acrivon Treeutics的股票進行了報道。他們對該股給予了“跑贏大盤”的評級。最後，傑富瑞金融集團在12月12日星期一的一份研究報告中對Acrivon治療公司的股票進行了報道。他們對該股給予了“買入”評級和17.00美元的目標價。

Get
到達
Acrivon Therapeutics
阿克瑞豐治療公司
alerts:
警報：

Acrivon Therapeutics Price Performance

Acrivon治療藥物性價比

Acrivon Therapeutics stock opened at $11.99 on Monday. Acrivon Therapeutics has a 52 week low of $10.90 and a 52 week high of $20.70.

Acrivon治療公司的股票週一開盤報11.99美元。Acrivon Treeutics的52周低點為10.90美元，52周高點為20.70美元。

Insider Activity

內幕活動

In other Acrivon Therapeutics news, major shareholder Ltd Chione purchased 400,000 shares of the stock in a transaction dated Thursday, November 17th. The shares were acquired at an average price of $12.50 per share, for a total transaction of $5,000,000.00. Following the completion of the acquisition, the insider now owns 3,856,597 shares of the company's stock, valued at approximately $48,207,462.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through
在Acrivon治療公司的其他消息中，大股東有限公司Chione在11月17日星期四的交易中購買了40萬股票。這些股票是以每股12.50美元的平均價格收購的，總交易額為5,000,000.00美元。收購完成後，這位內部人士現在擁有該公司3856,597股股票，價值約48,207,462.50美元。此次收購是在提交給美國證券交易委員會的一份檔案中披露的，該檔案可通過以下方式獲取
this link
這個環節
. In other Acrivon Therapeutics news, major shareholder Ltd Chione bought 400,000 shares of the company's stock in a transaction dated Thursday, November 17th. The shares were bought at an average price of $12.50 per share, for a total transaction of $5,000,000.00. Following the acquisition, the insider now directly owns 3,856,597 shares of the company's stock, valued at $48,207,462.50. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at
。在Acrivon治療公司的其他消息中，大股東有限公司Chione在11月17日星期四的一筆交易中購買了40萬股公司股票。這些股票是以每股12.50美元的平均價格購買的，總交易金額為5,000,000.00美元。收購完成後，這位內部人士現在直接持有該公司3856,597股股票，價值48,207,462.50美元。此次收購是在提交給美國證券交易委員會的一份檔案中披露的，該檔案可在
the SEC website
美國證券交易委員會網站
. Also, Director Ra Capital Management, L.P. purchased 3,389,500 shares of the firm's stock in a transaction that occurred on Thursday, November 17th. The shares were bought at an average price of $12.50 per share, with a total value of $42,368,750.00. Following the completion of the acquisition, the director now owns 4,384,206 shares of the company's stock, valued at approximately $54,802,575. The disclosure for this purchase can be found
。此外，董事在11月17日(星期四)的一次交易中購買了3389,500股該公司的股票。這些股票是以每股12.50美元的平均價格購買的，總價值為42,368,750.00美元。收購完成後，董事現在擁有該公司4,384,206股票，價值約54,802,575美元。關於這次購買的披露可以找到
here
這裡
.
.

About Acrivon Therapeutics

關於Acrivon治療公司

(Get Rating)

(獲取評級)

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to specific medicine by utilizing its proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3).

Acrivon治療公司是一家臨床階段的生物製藥公司，該公司致力於開發精確腫瘤學藥物，通過利用其基於蛋白質組學的患者回應者識別平臺Acrivon Predictive Precision Protetics(AP3)，將其與預測其腫瘤對特定藥物敏感的患者相匹配。

Read More

閱讀更多內容

  • Get a free copy of the StockNews.com research report on Acrivon Therapeutics (ACRV)
  • Is it Time to Take a Bite into Domino's Pizza?
  • MarketBeat: Week in Review 12/12 – 12/16
  • Which Two Bluechip Tech Companies Have Raised Their Guidance?
  • Should You Worry About Elon Musk Selling His Tesla Shares?
  • Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
  • 免費獲取StockNews.com關於Acrivon治療公司(ACRV)的研究報告
  • 是時候去Domino‘s Pizza嘗一口了嗎？
  • MarketBeat：回顧一週12/12-12/16
  • 哪兩家藍籌科技公司提高了他們的指引？
  • 你應該擔心埃隆·馬斯克出售他持有的特斯拉股票嗎？
  • 拖拉機庫存能否突破杯柄收購點？

Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

獲得Acrivon治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Acrivon Treeutics和相關公司的最新新聞和分析師評級的每日簡要摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論